"Designing Growth Strategies is in our DNA"

Next-Generation Sequencing (NGS) Market Size, Share and Industry Analysis By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Regional Forecast, 2019 - 2026

Region : Global | Latest Update: Sep, 2019 | Published Date: Jul, 2019 | Report ID: FBI101000| Status : Published

 

KEY INDUSTRY INSIGHTS

The global next-generation sequencing (NGS) market size was valued at USD 6,335.2 Million in 2018 and is Projected to Reach USD 31,411.3 Million by 2026, Exhibiting a CAGR of 22.2% between 2018 and 2026.


The growing demand for fast, cost-effective, and accurate DNA sequencing data interpretation has resulted in the birth and dominance of next-generation sequencing. Next-generation sequencing allows the sequencing of massive amount of DNA in a single run, thus facilitating the diagnosis of diseases and research. One of the major contributions of next-generation sequencing is genomics. The initiation of genomics projects in various countries such as the U.K., Qatar, and others is anticipated to favour the market. Also, the emergence of next-generation sequencing-based diagnostics and active government support for the same aree major factors for the expansion of the market.


Get comprehensive study about this report by, request a free sample copy


Key Market Drivers


Diversified Applications of Next-Generation Sequencing in Diagnostics, are Driving the Market


The lowered cost of sequencing has resulted in increasing the application of next-generation sequencing in diagnosis of diseases. Various test kits and testing services are emerging for the non-invasive pre-natal testing, cancer diagnosis, genetic testing, and others, which is driving the global market. Moreover, the active government support through product approval and improved reimbursement coverage for next-generation sequencing based-diagnostic tests is expected to provide new market growth opportunities. In addition, rising prevalence of chronic diseases, increased research, and start of high budget genomic projects is anticipated to further fuel the market during the forecast period.


Market Segmentation


Next-generation sequencing products include both instruments, software, and consumables. The product segment is estimated to dominate the market throughout the forecast period. The primary reasons responsible for its growth are the easy availability, high volume usage of consumables, and new product launch. The emerging need for new platform for accurate DNA data interpretation and advancements in bioinformatics has successfully contributed to increasing the number of startups for next-generation sequencing software and services.


To get details on market share, speak to our analyst


This has also rendered the services as the most attractive and lucrative segment in the Next-Generation Sequencing (NGS) market. The services segment is anticipated to have a remarkable growth during the forecast period owing to the decrease in cost of sequencing through next-generation sequencing, rapid adoption of genetic test, emerging guidelines, and health reimbursement policies. In terms of application, the market is divided into diagnostics, research and others. The diagnosis segment is estimated to account for a major portion of the next-generation sequencing market owing to the increasing adoption of genetic test, demand for cancer diagnosis, and increase in number of service providers.


In May 2018, Centers for Medicare & Medicaid Services (CMS) announced the National Coverage Determination to cover next-generation sequencing-based laboratory test for patients having cancer, which is projected to accelerate the growth of diagnosis segment. Various end users covered under the report are research institutes, healthcare facilities & diagnostic centres, pharmaceutical & biotechnological companies, and Contract Research Organization (CROs).


Regional Analysis


North America to Dominate the Market


North America dominated the market in 2018. The market in the region was valued at USD 2,331.4 Million in 2018. The active government support, direct presence of major manufacturers, and rising prevalence of cancer are the major factors for the expansion of North America in the market in the forecast duration. In September 2018, the FDA granted marketing approval for ClonoSEQ assay, a next-generation sequencing-based diagnostic test for minimal residual disease (MRD), in patients having acute lymphoblastic leukemia (ALL) or multiple myeloma, which is expected to augment the Next-Generation Sequencing (NGS) market share in North America.


In Europe, the market is estimated to expand owing to the increasing research investment, emphasis of precision medicines, and strategic collaborations. However, Asia Pacific is projected to report a remarkable growth owing to the increasing research activities, rising prevalence of genetic disorders, awareness on reproductive health, and improving healthcare infrastructure. The market in Latin America and Middle East & Africa is projected to register moderate CAGR during 2019-2026.


North America Next-Generation Sequencing Market Size, 2018

To get geographical overview of this market, request a free sample copy


Key Players


Illumina, Inc., F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc., to Account for the Largest Market Share in Terms of Revenue


Illumina, Inc., F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc., are estimated to acquire leading position in the Next-Generation Sequencing (NGS) market owing to their diversified product portfolio, strong geographical presence, and strategic partnerships. Illumina, Inc. acquired the top position in the market owing to the increasing sales of its products. In November 2017, Illumina announced the launch of NextSeq 550Dx instrument, the company’s second FDA approved and CE marked next-generation sequencing platform to diversify its diagnostic next-generation sequencing product portfolio and strengthening its position in the market. Other players operating in the NGS market are Agilent Technologies, Inc., QIAGEN, BGI, PerkinElmer Inc., Eurofins Scientific, Macrogen, Inc., PierianDx, and others.


Report Coverage


Sequencing of DNA fragments have helped in the diagnosis of diseases, research, drug discovery, forensics, and others. Next-generation sequencing, also called as high through-put sequencing is a useful platform that enables the sequencing of millions of DNA molecules simultaneously. The demand for next-generation sequencer is booming drastically, owing to its advantage of sequencing millions of DNA fragments in a single run. Many of the upcoming genetic tests such as Non-invasive Prenatal Testing (NIPT), Preimplantation Genetic Testing (PGT), virology, molecular testing, cancer diagnosis, and others are based on next-generation sequencing. The increasing clinical application of next-generation sequencing, increasing research, initiation of genome projects in various countries, adoption of personalized medicines, and advancements in bioinformatics are expected to further boost the market.


The report provides qualitative and quantitative insights on the next-generation sequencing industry analysis and detailed analysis of market size and growth rate for all possible segments in the market. The market segments includes type, application, end user, and region. Based on type, the Next-Generation Sequencing (NGS) market is segmented into products and services. The products segment is further bifurcated into instruments & software and consumables. In terms of application, the market is divided into diagnostics, research, and others.


Various end users of next-generation sequencing market, covered under the report are research institutes, healthcare facilities & diagnostic centers, pharmaceutical & biotechnological companies, Contract Research Organization (CROs). Geographically, the market is segmented into four major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.


Along with this, the report on NGS Market analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the overview of next-generation sequencing Next-Generation Sequencing (NGS) Market growth in terms of diagnostics test, new product launch, a regulatory scenario for key countries, startups with their funding overview, recent industry developments such as mergers & acquisitions, and key industry trends.


KEY SEGMENTS WITHIN THE MARKET


To get information on various segments, share your queries with us


SEGMENTATION


























 SEGMENTATION



 DETAILS



By Type




  • Products

  • Instruments & Software

  • Consumables

  • Services



By Application




  • Diagnostics

  • Research

  • Others



By End User




  • Research Institutes

  • Healthcare Facilities & Diagnostic Centers

  • Pharmaceutical & Biotechnological Companies

  • Contract Research Organization (CROs)



By Geography




  • North America (the USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)



NGS Market Players



  • Illumina, Inc.

  • Thermo Fisher Scientific Inc.

  • Hoffmann-La Roche Ltd

  • Agilent Technologies, Inc.

  • QIAGEN

  • BGI

  • PerkinElmer Inc.

  • Eurofins Scientific

  • Macrogen, Inc.

  • PierianDx

  • Other prominent players


Key Industry Developments



  • In June 2019, Saphetor announced its partnership with Swift Biosciences Inc. aiming to accelerate and standardize data interpretation solution for targeted next-generation sequencing panels.

  • In January 2019, PierianDx announced partnership with Illumina to provide the customers with informatics services for Illumina’s oncology products further supporting cancer diagnostics and research.

  • In November 2017, Illumina, announced the launch of NextSeq 550Dx instrument, the company’s second FDA and CE marked next-generation sequencing platform to diversify its diagnostic next-generation sequencing product portfolio.

  • In September 2018, the FDA granted marketing approval to ClonoSEQ assay, a next-generation sequencing-based diagnostic test developed by Adaptive Biotechnologies Corp. for minimal residual disease (MRD), in patients having acute lymphoblastic leukemia (ALL) or multiple myeloma

  • In June 2018, Agilent Technologies announced the launch of Agilent OnePGT, a next-generation sequencing solution for Preimplantation Genetic Testing (PGT).


We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X